Development of a membrane-disruption assay using phospholipid vesicles as a proxy for the detection of cellular membrane degradation [PDF]
Snakebite envenoming is a global health issue that affects millions of people worldwide, and that causes morbidity rates surpassing 450,000 individuals annually.
Mátyás A. Bittenbinder +7 more
doaj +7 more sources
In vitro inhibition of snake venom toxins by varespladib, marimastat, nafamostat and dimercaprol
Anandie le Roux +3 more
semanticscholar +3 more sources
Varespladib (LY315920) is a potent inhibitor of human group IIA phospholipase A2 (PLA2) originally developed to control inflammatory cascades of diseases associated with high or dysregulated levels of endogenous PLA2. Recently, varespladib was also found to inhibit snake venom PLA2 and PLA2-like toxins.
Daniela P. Marchi‐Salvador +8 more
semanticscholar +6 more sources
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial [PDF]
IMPORTANCE: Secretory phospholipase A2(sPLA2) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes ...
Abraham, J +369 more
core +7 more sources
The treatment for snakebites is early administration of antivenom, which can be highly effective in inhibiting the systemic effects of snake venoms, but is less effective in the treatment of extra-circulatory and local effects. To complement standard-of-care treatments such as antibody-based antivenoms, natural and synthetic small molecules have been ...
Daniela P. Marchi‐Salvador +4 more
semanticscholar +7 more sources
The venoms of Australasian elapid snakes are known to possess coagulant activity, including some with strong procoagulant activity and others with anticoagulant activity, although the latter are less well known. This study investigates the anticoagulant activity of Australasian elapid snake venoms, and whether this activity is neutralised by commercial
Kate Murphy +3 more
semanticscholar +4 more sources
Neutralizing Effects of Small Molecule Inhibitors and Metal Chelators on Coagulopathic Viperinae Snake Venom Toxins [PDF]
Animal-derived antivenoms are the only specific therapies currently available for the treatment of snake envenoming, but these products have a number of limitations associated with their efficacy, safety and affordability for use in tropical snakebite ...
Chunfang Xie +6 more
doaj +5 more sources
Wasp venom-induced acute kidney injury: current progress and prospects [PDF]
Wasp venom can trigger local and systemic reactions, with the kidneys being commonly affected, potentially causing acute kidney injury (AKI). Despite of the recent advances, our knowledge on the underlying mechanisms of toxicity and targeted therapies ...
Fanglin Yu +5 more
doaj +2 more sources
Optimizing drug discovery for snakebite envenoming via a high-throughput phospholipase A2 screening platform [PDF]
Snakebite envenoming is a neglected tropical disease that causes as many as 1.8 million envenomings and 140,000 deaths annually. To address treatment limitations that exist with current antivenoms, the search for small molecule drug-based inhibitors that
Laura-Oana Albulescu +12 more
doaj +2 more sources
The Urgent Need to Develop Novel Strategies for the Diagnosis and Treatment of Snakebites [PDF]
Snakebite envenoming (SBE) is a priority neglected tropical disease, which kills in excess of 100,000 people per year. Additionally, many millions of survivors also suffer through disabilities and long-term health consequences. The only treatment for SBE,
Harry F. Williams +6 more
doaj +3 more sources

